ADVM:NSD-Adverum Biotechnologies, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 10.30

Change

-0.15 (-1.44)%

Market Cap

USD 1.05B

Volume

1.29M

Average Target Price

USD 22.57 (+119.14%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, engages in developing gene therapy product candidates to treat ocular and rare diseases. Its pipeline of product candidates includes ADVM-022, an adeno- associated virus (AAV). 7m8-aflibercept for the treatment of wet age-related macular degeneration; ADVM-043, an investigational gene therapy candidate for the treatment of alpha-1 antitrypsin deficiency; and ADVM-053, a preclinical gene therapy product candidate for the treatment of hereditary angioedema. The company has collaboration agreements with Editas Medicine, Inc. to leverage its proprietary AAV vectors for genome editing technologies to treat up to five inherited retinal diseases; and Regeneron Pharmaceuticals, Inc. for the development of up to eight distinct ocular therapeutic targets. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was founded in 2006 and is headquartered in Redwood City, California.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-09-30 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

+1.81 (+0.67%)

USD70.41B 33.27 26.59
REGN Regeneron Pharmaceuticals, Inc

-13.83 (-2.41%)

USD61.03B 21.61 16.69
SGEN Seattle Genetics, Inc

+4.73 (+2.48%)

USD33.38B N/A N/A
MRNA Moderna, Inc

+0.23 (+0.33%)

USD28.71B N/A N/A
BGNE BeiGene, Ltd

+4.98 (+1.77%)

USD25.50B N/A N/A
RPRX Royalty Pharma plc

+0.06 (+0.14%)

USD25.49B 34.81 9.50
ALXN Alexion Pharmaceuticals, Inc

+1.97 (+1.75%)

USD24.65B 29.87 27.00
GMAB Genmab A/S

-0.72 (-1.93%)

USD23.71B 25.56 2.87
IMMU Immunomedics, Inc

-0.22 (-0.26%)

USD19.71B N/A N/A
INCY Incyte Corporation

+2.31 (+2.64%)

USD19.19B 47.64 35.20

ETFs Containing ADVM

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -10.59% 44% F 46% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -10.59% 44% F 45% F
Trailing 12 Months  
Capital Gain 83.11% 74% C 87% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 83.11% 74% C 87% B+
Trailing 5 Years  
Capital Gain 21.32% 70% C- 59% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 21.32% 70% C- 54% F
Average Annual (5 Year Horizon)  
Capital Gain 48.79% N/A N/A 92% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 48.79% N/A N/A 92% A-
Risk Return Profile  
Volatility (Standard Deviation) 88.11% N/A N/A 11% F
Risk Adjusted Return 55.38% N/A N/A 74% C
Market Capitalization 1.05B 77% C+ 71% C-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 3.62 53% F 34% F
Price / Cash Flow Ratio -21.35 83% B 88% B+
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -37.87% 75% C 28% F
Return on Invested Capital -36.40% 75% C 23% F
Return on Assets -20.86% 66% D 19% F
Debt to Equity Ratio 0.06% 88% B+ 93% A
Technical Ratios  
Short Ratio 8.95 25% F 16% F
Short Percent 11.75% 26% F 19% F
Beta 1.70 38% F 21% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

What to not like:
Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector